ABL1 and gastrointestinal stromal tumor: They include imatinib mesylate (or “Gleevec”/“Glivec”) for BCR-ABL inhibition in Chronic Myeloid Leukemia (CML) [9] and for KIT inhibition in gastrointestinal stromal tumors (GIST) [10], respectively.